Advertisement
Screener

BIOATLA, INC. (BCAB) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

BIOATLA, INC. Increase (Decrease) in Deferred Revenue

BIOATLA, INC. (BCAB) reported Increase (Decrease) in Deferred Revenue of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2022-02-28

  • BIOATLA, INC. increase (decrease) in deferred revenue for the quarter ending 2021-12-31 was $0.00.
  • BIOATLA, INC. increase (decrease) in deferred revenue for the quarter ending 2021-09-30 was $0.00.
  • BIOATLA, INC. increase (decrease) in deferred revenue for the quarter ending 2021-06-30 was $0.00.
  • BIOATLA, INC. increase (decrease) in deferred revenue for the quarter ending 2021-03-31 was $0.00.
  • BIOATLA, INC. increase (decrease) in deferred revenue for fiscal 2021 was $0.00.
  • BIOATLA, INC. increase (decrease) in deferred revenue for fiscal 2020 was -$429.00K, a 102.17% decline from fiscal 2019.
  • BIOATLA, INC. increase (decrease) in deferred revenue for fiscal 2019 was $19.76M.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$0.00
derived: sum of 2 quarters · filed 2022-02-28
$0.00
derived: sum of 3 quarters · filed 2022-02-28
$0.00
10-K · filed 2022-02-28
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$0.00
derived: sum of 2 quarters · filed 2021-11-15
$0.00
10-Q · filed 2021-11-15
$0.00
derived: sum of 4 quarters · filed 2022-02-28
2021-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13
$0.00
10-Q · filed 2021-08-13
$0.00
derived: sum of 3 quarters · filed 2022-02-28
-$150.00K
derived: sum of 4 quarters · filed 2022-02-28
2021-03-31$0.00
10-Q · filed 2021-05-12
$0.00
derived: sum of 2 quarters · filed 2022-02-28
-$150.00K
derived: sum of 3 quarters · filed 2022-02-28
-$340.00K
derived: sum of 4 quarters · filed 2022-02-28
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
-$150.00K
derived: sum of 2 quarters · filed 2022-02-28
-$340.00K
derived: sum of 3 quarters · filed 2022-02-28
-$429.00K
10-K · filed 2022-02-28
2020-09-30-$150.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
-$340.00K
derived: sum of 2 quarters · filed 2021-11-15
-$429.00K
10-Q · filed 2021-11-15
2020-06-30-$190.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13
-$279.00K
10-Q · filed 2021-08-13
2020-03-31-$89.00K
10-Q · filed 2021-05-12
2019-12-31$19.76M
10-K · filed 2022-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
EXOZYMES INC. (EXOZ)United States$0.058B
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Tevogen Inc. (TVGN)United States$0.049B
Instil Bio, Inc. (TIL)United States$0.048B-1.73
LeonaBio, Inc. (LONA)United States$0.047B-0.61
BioStem Technologies, Inc. (BSEM)United States$0.069B
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02